Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

633 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.
Ozga M, Nicolet D, Mrózek K, Walker CJ, Blachly JS, Kohlschmidt J, Orwick S, Carroll AJ, Larson RA, Kolitz JE, Powell BL, Stone RM, Byrd JC, Eisfeld AK, Mims AS. Ozga M, et al. Among authors: larson ra. Am J Hematol. 2024 Nov;99(11):2236-2240. doi: 10.1002/ajh.27465. Epub 2024 Sep 16. Am J Hematol. 2024. PMID: 39283025 No abstract available.
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
Lin C, Patel AA, Huo D, Karrison T, van Besien K, Godwin J, Sher D, Weiner H, Green M, Wade JL 3rd, Klisovic R, Baer MR, Larson RA, Stock W, Odenike O. Lin C, et al. Among authors: larson ra. Blood Adv. 2024 Nov 26;8(22):5735-5743. doi: 10.1182/bloodadvances.2024013215. Blood Adv. 2024. PMID: 39250708 Free PMC article. Clinical Trial.
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Wei AH, Löwenberg B. Döhner H, et al. Among authors: larson ra. Blood. 2024 Nov 21;144(21):2169-2173. doi: 10.1182/blood.2024025409. Blood. 2024. PMID: 39133932
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. Among authors: larson ra. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. N Engl J Med. 2024. PMID: 38820078 Clinical Trial.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer MW. Roloff GW, et al. Among authors: larson ra. Haematologica. 2024 Nov 1;109(11):3739-3744. doi: 10.3324/haematol.2023.284584. Haematologica. 2024. PMID: 38618681 Free PMC article. No abstract available.
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel AA. Madero-Marroquin R, et al. Among authors: larson ra. Leuk Lymphoma. 2024 Jun;65(6):864-867. doi: 10.1080/10428194.2024.2324991. Epub 2024 Mar 5. Leuk Lymphoma. 2024. PMID: 38441062 No abstract available.
633 results